Johnson & Johnson (JNJ)
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial
A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now
For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
3 Under-the-Radar Dividend Stocks Quietly Beating the Market
For reasons that seem pretty obvious, dividend investors tend to chase the most familiar names like Pepsi (NYSE:PEP), Johnson and Johnson (NYSE:JNJ), and Procter & Gamble (NYSE:PG), and they do so for a lot of the right reasons.
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.
The Dividend Stocks That Keep Paying Even When Markets Stumble
When it comes to weathering market volatility, there is no easy answer, and what's worse is that when investors, retail or otherwise, try to time the market, it usually ends in disaster.
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
